Cancer Immunology ImmunotherapyImmunologyPeer-reviewed journal article
TRAIL orchestrates ThINKK-induced NK cell cytotoxicity against childhood acute lymphoblastic leukemia
Emilie Ollame-Omvane, Leila Ben Khemis, Paulo CordeiroiD, Claire FuchsiD, Alex Richard-St-HilaireiD, Kathie BélandiD, Élie HaddadiD, Daniel SinnettiD, Sabine HerblotiD, Michel DuvaliD
Abstract
BackgroundTherapeutic Inducers of Natural Killer cell Killing (ThINKK) represent a novel class of immunotherapy designed to enhance the graft-versus-leukemia effect of hematopoietic stem cell transplantation in pediatric patients with high-risk or relapse leukemia. Our previous work identified high expression of TRAIL as a key signature of Natural Killer (NK) cell stimulation by ThINKK. In this study, we aim to elucidate the mechanisms underlying acute lymphoblastic leukemia (ALL) killing by ThINNK-stimulated NK cells and to identify predictive sensitivity markers of this innovative approach. MethodsWe performed NK cell cytotoxic assays using a panel of genetically diverse ALL cell lines and patients samples. Gene deletion and gene enforced expression in sensitive or resistant cell lines were performed to demonstrate the role of TRAIL-receptors expression and death receptor signaling pathway in ALL cell death induced by ThINKK-stimulated NK cells. These findings were further validated through the analysis of primary patients samples and transcriptomic profiling of a cohort of 320 ALL patients from the CHU Sainte-Justine. ResultsWe found that ALL sensitivity to ThINKK-stimulated NK cell killing was independent of their genetic background or their HLA expression. In addition, our data revealed the dual role of TRAIL: first, a strong NK cell activating receptor that induced rapid killing of ALL expressing TRAIL-R2, and second, a death-receptor ligand inducing ALL apoptosis following sustained engagement with its receptors. The transcriptomic analysis of ALL patients samples indicated that TRAIL-R2 and TRAIL-R1 are widely expressed across ALL subtypes and are not downregulated at relapse. ConclusionThese findings support the use of TRAIL receptor expression as a biomarker of sensitivity to ThINKK immunotherapy and establish a mechanistic framework to guide patient stratification and therapeutic optimization.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 49%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-cell transcriptomics reveals that tumor-infiltrating natural killer cells are activated by localized ablative immunotherapy and share anti-tumor signatures induced by immune checkpoint inhibitors
K. Liu, N. Sadeghipour, … W. R. Chen·bioRxiv·May 2, 2023
- Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease
Hongwei Ren, Natalina Elliott, … Anastasios Karadimitris·bioRxiv·Jan 22, 2025
- Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells
H. Alizadeh Zeinabad, W. J. Yeoh, … E. Szegezdi·bioRxiv·Sep 9, 2022
- The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias.
R. Hallal, M. De Toledo, … G. Bossis·bioRxiv·Feb 19, 2024
- Use of CD122+ natural killer cell precursors for superior anti-leukemia responses.
S. Guglietta, L. Cardenas, C. Krieg·bioRxiv·Oct 24, 2022
- Natural killer cell cytotoxicity shapes the clonal evolution of B cell leukaemia
M. C. Buri, M. R. Shoeb, … E. M. Putz·bioRxiv·Nov 16, 2023